Non-Eosinophilic Neutrophilic Asthma

Completed

• Conditions: Neutrophilic Asthma

• Registration Number: NCT03479138
• Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Brief Summary

Define and characterize the neutrophilic phenotype of severe asthma.

Detailed Description

Neutrophilic asthma (NA) is the asthma phenotype less known, causes a severe disease and does not have a specific treatment. Research on the neutrophilia mechanisms, new neutrophil (NEU) types and bronchial microbiome, can provide an opportunity to better understand the NA pathogenesis.

OBJECTIVES: 1. To describe the clinical characteristics of NA and its sub-phenotypes (SUBSTUDY 1); 2. To determine the NEU types associated with the NA and its sub-phenotypes (SUBSTUDY 2); and 3. To identify the bronchial microbiological flora of the NA, specifically related to lung microbiome and the immune response against Chlamydia Pneumoniae (SUBSTUDY 3).

METHODS: Multicenter prospective study including 100 patients with severe asthma (GINA/GEMA criteria): 50 with non-neutrophilic asthma (\<65% NEU in induced sputum \[IS\]); and 50 with NA (\> 64% NEU in IS). SUBSTUDY 1: clinical variables (years of evolution, exacerbations, asthma control test, mini asthma quality of life questionnary), comorbidities (GERD, nasal polyposis, obesity, ASS), pulmonary function (FEV1, exhaled fraction of nitric oxide, total lung capacity, Aspergillus), prick-test and CT scan chest; SUBSTUDY 2 (in IS and plasma): apoptotic index by means NE culture and flux cytometer (Annexin-V-FITC), NEU phenotype by surface markers (CD16, CD66b, CD62L, HLADR, CD177, CD11b, CD63, CXCR2, CXCR4) with density gradient study and determination of cytokines (IL-6, IL-8, IL-17, IL-1, IL-22) by ELISA; SUBSTUDY 3 (in IS): bronchial microbiome for 16 subunit rRNA by Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt), and anti-Chlamydia Pneumoniae Immunoglobuling A by ELISA.

Study Timeline

• Study Start: 2018-02-21
• Study First Submitted: 2018-03-14
• Study First Submitted QC: 2018-03-20
• Study First Posted: 2018-03-27
• Status Verified: 2022-10
• Primary Completion: 2023-06-30
• Study Completion: 2023-07-30
• Last Update Submitted: 2024-01-10
• Last Update Posted: 2024-01-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• 18 - 80 years old
• Confirmed diagnosis of asthma (according to spanish guideline GEMA)
• Severe persistent asthma (step 5-6 GEMA)
• Eosinophils<300/mm3 in peripheral blood

Exclusion Criteria

• Respiratory infection during the previous month
• Significant lung pathology not attributable to asthma (bronchiectasis with Reiff score>3)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Phenotype of neutrophils	24 hours	To determine the types of neutrophils (in induced sputum and blood) associated with neutrophilic asthma and its subphenotypes according to flow cytometry
Microbiome analysis	6 months	To analyse the bronchial microbiological flora of neutrophilic asthma

Secondary Outcome Measures

Name	Time	Method
Demographic characteristics	1 year	To describe demographic characteristics
Clinical demographic characteristics	1 year	To describe the clinical characteristics and natural history of the neutrophilic asthma and its subphenotypes

Trial Locations

Locations (2)

Hospital de la Santa Creu i Sant Pau. Carrer Mas Casanovas 90.; 🇪🇸 Barcelona, Spain

Hospital de la Santa Creu i Sant Pau; 🇪🇸 Barcelona, Spain